Share-based Payment Arrangement, Expense in USD of Acrivon Therapeutics, Inc. from Q3 2021 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2021 to Q3 2025.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $3.91M, a 6.54% increase year-over-year.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $15.3M, a 12.4% increase year-over-year.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $14.3M, a 23% increase from 2023.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11.6M, a 432% increase from 2022.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.19M, a 340% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Acrivon Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $15.3M $3.91M +$240K +6.54% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $15.1M $3.93M +$361K +10.1% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 $14.7M $3.79M +$447K +13.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $14.3M $3.71M +$649K +21.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 $13.6M $3.67M +$443K +13.7% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $13.2M $3.57M +$880K +32.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 $12.3M $3.34M +$698K +26.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 $11.6M $3.06M +$1.41M +85.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 $10.2M $3.23M +$2.96M +1109% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $7.25M $2.69M +$2.45M +1053% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $4.79M $2.65M +$2.61M +6685% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $2.19M $1.65M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $267K +$240K +889% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $233K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $39K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 $27K Jul 1, 2021 Sep 30, 2021 10-Q 2022-12-15

Acrivon Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $14.3M +$2.67M +23% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 $11.6M +$9.43M +432% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
2022 $2.19M +$1.69M +340% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $497K Jan 1, 2021 Dec 31, 2021 10-K 2023-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.